Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading activity on Wednesday. Stock investors purchased 22,307 call options on the stock. This is an increase of 48% compared to the typical daily volume of 15,028 call options.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $3.80 on Friday. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.01 billion, a P/E ratio of -3.17 and a beta of 1.00. The firm’s 50-day moving average price is $3.31 and its 200-day moving average price is $3.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The company had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. Recursion Pharmaceuticals’s revenue for the quarter was down 56.8% on a year-over-year basis. During the same period last year, the business earned ($0.50) EPS. As a group, equities analysts anticipate that Recursion Pharmaceuticals will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. reduced their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Morgan Stanley lifted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.10.

Insider Buying and Selling

In other news, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the completion of the transaction, the director directly owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. The trade was a 0.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 121,937 shares of company stock valued at $421,574 in the last three months. 6.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the last quarter. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after acquiring an additional 3,771,357 shares during the period. State Street Corp raised its position in Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after acquiring an additional 7,064,963 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Recursion Pharmaceuticals by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after acquiring an additional 1,310,695 shares during the period. Finally, Norges Bank acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $23,473,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.